{"version":"1.0","type":"link","title":"Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.","author_name":"Budde LE 외","author_url":"https://prs-insight.online/author/Budde%20LE","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/158408","thumbnail_width":1200,"thumbnail_height":630}